A National Formulary for Canada
| dc.contributor.author | Hollis, Aidan | |
| dc.contributor.author | Law, Stephen, M. | |
| dc.date.accessioned | 2023-06-07T20:32:46Z | |
| dc.date.available | 2023-06-07T20:32:46Z | |
| dc.description.abstract | This article analyzes the benefits and costs of replacing Canada's ten different provincial formularies with one single national formulary. The 2002 Romanow Commission on the Future of Health Care in Canada recommended that Canada should have a National Drug Agency which would maintain a national formulary, replacing the existing provincial formularies which balkanize drug markets across Canada. This recommendation has been in part incorporated into the "Common Drug Review" in which the provinces (excluding Québec) have agreed to undertake a single evaluation of all new drugs; provinces, however, retain their own formularies and decide which products to list. This balkanized approach to listing and insurance coverage of drugs substantially weakens the bargaining position of the provinces and leads to higher costs. | |
| dc.identifier.uri | https://unbscholar.lib.unb.ca/handle/1882/34448 | |
| dc.language.iso | English | |
| dc.rights | http://purl.org/coar/access_right/c_16ec | |
| dc.title | A National Formulary for Canada | |
| dc.type | senior report | |
| thesis.degree.level | undergraduate |